Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Arrowhead Pharmaceuticals (ARWR) over the last 11 years, with Q4 2025 value amounting to $0.36.

  • Arrowhead Pharmaceuticals' Debt to Equity fell 9510.6% to $0.36 in Q4 2025 from the same period last year, while for Dec 2025 it was $0.36, marking a year-over-year decrease of 9510.6%. This contributed to the annual value of $0.51 for FY2025, which is 7539.66% down from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Debt to Equity stood at $0.36 for Q4 2025, which was down 9510.6% from $0.51 recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' 5-year Debt to Equity high stood at $7.3 for Q4 2024, and its period low was $0.36 during Q4 2025.